Pharmaceutical - Immunologicals

Filter

Current filters:

Immunologicals

Popular Filters

1 to 25 of 98 results

GlaxoSmithKline drops option for Dynavax’ DV1179

28-11-2014

USA-based Dynavax Technologies (Nasdaq: DVAX) today announced that it has regained full rights to DV1179,…

DV1179Dynavax TechnologiesGlaxoSmithKlineImmunologicalsLicensingPharmaceuticalResearch

ALK Abello files for European approval for its dust mite allergy sublingual tablets

ALK Abello files for European approval for its dust mite allergy sublingual tablets

20-11-2014

Denmark-based allergy specialist ALK Abello has filed a registration application for its house dust mite…

ALK AbelloDenmarkImmunologicalsPharmaceuticalRegulation

Sanofi showcases next wave of medicines and vaccines

20-11-2014

French pharma major Sanofi is today outlining its intention to launch high-potential new medicines and…

Cardio-vascularDiabetesHealth Medical PharmaImmunologicalsNeurologicalPharmaceuticalPharmaceutical industryRare diseasesResearchSanofiUnited StatesVaccines

AstraZeneca and University of Glasgow partner to form immunology discovery center

AstraZeneca and University of Glasgow partner to form immunology discovery center

04-11-2014

The University of Glasgow and Anglo-Swedish drug major AstraZeneca have now officially launched the GLAZgo…

AstraZenecaImmunologicalsPharmaceuticalResearchUK

Lilly to drop Ph III tabalumab trial in lupus due to poor efficacy

Lilly to drop Ph III tabalumab trial in lupus due to poor efficacy

02-10-2014

US pharma major Eli Lilly has said it will discontinue development of tabalumab, which is being studied…

Anti-Arthritics/RheumaticsEli LillyImmunologicalsPharmaceuticalResearchtabalumabUSA

Pfizer and Kyowa Hakko collaborate on immuno-oncology combination study

Pfizer and Kyowa Hakko collaborate on immuno-oncology combination study

30-09-2014

US pharma major Pfizer and Japanese drugmaker Kyowa Hakko Kirin have entered into an agreement to explore…

ImmunologicalsKyowa Hakko KirinmogamulizumabOncologyPF-05082566PfizerPharmaceuticalResearchUSA

Takeda and BioMotiv in strategic partnership, including investment

Takeda and BioMotiv in strategic partnership, including investment

25-09-2014

Japan’s largest drugmaker Takeda Pharmaceutical has made a strategic investment in USA-based BioMotiv,…

BioMotivCardio-vascularFinancialImmunologicalsInflammatory diseasesJapanPharmaceuticalResearchTakeda PharmaceuticalUSA

Merck Serono on track with pharma strategy

Merck Serono on track with pharma strategy

18-09-2014

Germany’s Merck KGaA says that its biopharmaceutical division - Merck Serono - is well on track with…

ataciceptBiosimilarsFinancialGermanyImmunologicalsMerck KGaAMerck SeronoOncologyPharmaceuticalResearchTH-302

Teijin inks exclusive deal with Sigma-Tau for EZN-2279 in Japan

Teijin inks exclusive deal with Sigma-Tau for EZN-2279 in Japan

26-06-2014

Japanese firm Teijin has entered into an agreement with the UK subsidiary of privately-owned Italian…

EZN-2279ImmunologicalsJapanLicensingPharmaceuticalSigma-TauTeijin

Ligand in licensing deal with TG Thera for IRAK-4 inhibitor program

Ligand in licensing deal with TG Thera for IRAK-4 inhibitor program

24-06-2014

US drugmaker Ligand Pharmaceuticals has signed an exclusive global license accord with TG Therapeutics…

ImmunologicalsLicensingLigand PharmaceuticalsOncologyPharmaceuticalTG Therapeutics

Positive opinion from CHMP for Veloxis’ Envarsus

22-05-2014

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has today adopted…

EnvarsusEuropeImmunologicalsPharmaceuticalRegulationVeloxis Pharmaceuticals

FDA approves Merck’s Ragwitek for short ragweed pollen allergies

18-04-2014

The US Food and Drug Administration has approved US pharma giant Merck & Co’s Biological License Application…

ALK AbelloImmunologicalsMerck & CoNorth AmericaPharmaceuticalRagwitekRegulationUSA

US FDA approves Stallergenes’ allergy tablet Oralair

US FDA approves Stallergenes’ allergy tablet Oralair

02-04-2014

The US Food and Drug Administration has approved Oralair immunotherapy tablet from French allergen specialist…

ImmunologicalsOralairPharmaceuticalRegulationStallergenesUSA

Sanofi and UCB in immune-mediated diseases research partnership

Sanofi and UCB in immune-mediated diseases research partnership

11-03-2014

French pharma major Sanofi and UCB, Belgium’s largest drugmaker, have entered into a scientific and…

Anti-Arthritics/RheumaticsGastro-intestinalsImmunologicalsPharmaceuticalResearchSanofiUCB

ALK’s partner for Japan reports positive trial results for house dust mite SLIT-tablet

10-03-2014

Denmark-based allergy specialist ALK Abello said that its Japanese partner Torii Pharmaceutical has reported…

ALK AbelloDenmarkImmunologicalsJapanPharmaceuticalResearchTorii Pharma

AAAAI 2014: Roche’s lebrikizumab shows reduction of asthma attack rates

AAAAI 2014: Roche’s lebrikizumab shows reduction of asthma attack rates

05-03-2014

Swiss drug major Roche has presented new data from the LUTE / VERSE Phase IIb studies for the investigational…

ImmunologicalslebrikizumabPharmaceuticalResearchRespiratory and PulmonaryRocheUSA

AAAAI 2014: Merck announces positive results of study in sublingual dust allergen immunotherapy tablet

AAAAI 2014: Merck announces positive results of study in sublingual dust allergen immunotherapy tablet

05-03-2014

Pharma giant Merck & Co has announced results from a Phase IIb study evaluating two doses of its investigational…

ImmunologicalsMerck & CoPharmaceuticalResearchUSA

Funding restrictions for rituximab and eltrombopag widened in New Zealand

Funding restrictions for rituximab and eltrombopag widened in New Zealand

20-02-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC has announced the approval of proposals to widen…

Asia-PacificeltrombopagFinancialGlaxoSmithKlineHealthcareImmunologicalsNew ZealandPharmaceuticalrituximabRoche

Inovio announces new additions to senior management team

Inovio announces new additions to senior management team

18-02-2014

US drug developer Inovio Pharmaceuticals has expanded its senior management team with two appointments…

BoardroomImmunologicalsInovio PharmaceuticalsPharmaceuticalUSA

Scancell granted orphan drug designation for melanoma drug

Scancell granted orphan drug designation for melanoma drug

17-02-2014

UK-based immunotherapy company Scancell has been granted orphan drug designation for its SCIB1 ImmunoBody…

ImmunologicalsOncologyPharmaceuticalRegulationScancellSCIB1UKUSA

1 to 25 of 98 results

Back to top